INSIGHT, page-3

Immutep has never had the resources to evaluate companion diagnostics and determine which patients might most benefit from IMP321. The APC activation inside the tumor stroma accompanied by an explanation with tissue bio markers de-risk as proof of concept. This isn’t just a small study, but a potential paradigm shift in how patients are treated. Remember how sick these patients have to be to even have subcutaneous access to the tumor. Lumps are late stage, and we do know they couldn’t possibly be alive several months later without intervention. It’s working, and if biomarkers can explain why it’s huge.